Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gilead Sciences

114.75
+0.32000.28%
Volume:3.76M
Turnover:427.63M
Market Cap:142.90B
PE:301.97
High:114.87
Open:113.15
Low:112.82
Close:114.43
Loading ...

BUZZ-Street View: Analysts optimistic on Gilead's outlook with strong HIV drug sales

Reuters
·
12 Feb

Gilead Sciences Shares up 4.5% Premarket After Co Forecasts FY25 Profit Above Estimates

THOMSON REUTERS
·
12 Feb

U.S. RESEARCH ROUNDUP-Edison International, Onestream, Vertex Pharmaceuticals

Reuters
·
12 Feb

Gilead Sciences Inc (GILD) Q4 2024 Earnings Call Highlights: Strong Growth in HIV and Oncology Segments

GuruFocus
·
12 Feb

Gilead : Piper Sandler Raises Target Price to $110 From $105

THOMSON REUTERS
·
12 Feb

Gilead Sciences Reports Strong 2024 Financial Performance

TIPRANKS
·
12 Feb

Gilead Sciences: Strong Financial Performance and Promising Future Prospects Justify Buy Rating

TIPRANKS
·
12 Feb

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript

Motley Fool Transcribing
·
12 Feb

24H|Super Micro Jumps 7%; Upstart Soars 27%; Firefly Neuroscience Surges Another 18% After Soaring 171%

Tiger Newspress
·
12 Feb

Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks
·
12 Feb

Gilead's HIV Segment Buoying Product Sales Amid Covid Losses -- Market Talk

Dow Jones
·
12 Feb

Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates

Zacks
·
12 Feb

Gilead Sciences Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
12 Feb

Gilead Sciences (GILD) Q4 2024 Earnings: EPS of $1.42 Beats Estimates, Revenue Surpasses Expectations at $7.6 Billion

GuruFocus
·
12 Feb

Stock Track | Gilead Sciences Soars 5.32% After Hours on Strong Q4 Results, Upbeat Outlook

Stock Track
·
12 Feb

Gilead Sciences Q4 Non-GAAP Earnings, Revenue Rise -- Shares Up After Hours

MT Newswires Live
·
12 Feb